Stock Information
symbol line chart

IMDXInsight Molecular Diagnostics Inc.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Joshua Riggs

Location

Tennessee, USA

Exchange

Nasdaq

Website

https://oncocyte.com

Summary

OncoCyte Corporation researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.

Company Info

CEO

Joshua Riggs

Location

Tennessee, USA

Exchange

Nasdaq

Website

https://oncocyte.com

Summary

OncoCyte Corporation researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.

AI Insights for IMDX
5 min read

Quick Summary

Insight Molecular Diagnostics Inc., trading on Nasdaq as IMDX, is a molecular diagnostics company that researches, develops, and commercializes laboratory-developed tests and related diagnostic technologies. The company was formerly known as OncoCyte Corporation and has repositioned its identity around precision molecular diagnostics that extend beyond oncology into transplant medicine. Its offerings include tests for early-stage lung cancer risk stratification, immune-response profiling, transplant rejection monitoring, biomarker discovery, assay development, and clinical trial support. Its main customers include physicians, transplant centers, oncology practices, clinical laboratories, researchers, pharmaceutical companies, and academic medical centers. The company is small, with about 120 employees, limited current revenue, and a business model that depends heavily on commercialization progress, reimbursement access, clinical adoption, and regulatory execution.

Strengths

•

IMDX’s main strength is its focus on precision molecular diagnostics, a market where clinical decision-making increasingly depends on genomic, immune, and molecular biomarkers.

•

The company has a defined transplant diagnostics strategy built around donor-derived cell-free DNA, a clinically relevant biomarker for rejection risk monitoring.

•

Its GraftAssure product family gives the company a clearer and more unified brand architecture following the rebrand from OncoCyte.

•

The company also has existing oncology assets such as DetermaRx and DetermaIO, which provide experience in molecular test development and commercialization.

•

Its CLIA-certified laboratory operations, research capabilities, and service offerings may help support partnerships with transplant centers, researchers, and biopharma customers.

Key Risks

•

IMDX faces substantial financial, regulatory, commercial, and competitive risks.

•

Its losses are large relative to its current revenue, which may create financing risk or shareholder dilution if the company needs additional capital.

•

Regulatory changes affecting laboratory-developed tests, FDA requirements, CMS reimbursement, or payer coverage could materially affect the business.

•

The company also faces strong competition from established transplant diagnostics and oncology diagnostics companies that have greater resources and market presence.

What to Watch

During the most recent reported quarter, IMDX remained a very early-revenue diagnostics company with total revenue of about $239,000 and gross profit of about $157,000.
The company posted a significant operating loss of about $11.4 million and net income of about negative $11.26 million, showing that expenses remain far above current revenue.
The reported EPS was negative $0.31 on both a basic and diluted basis, which reinforces that the business is still in an investment and commercialization phase.
There was no dividend, no earnings yield, and no near-term earnings date provided in the supplied data.
The company’s rebrand from OncoCyte to Insight Molecular Diagnostics, its new IMDX ticker, its headquarters relocation to Nashville, and the consolidation of transplant products under the GraftAssure brand were key strategic developments in the recent news flow.

Price Drivers

•

IMDX’s stock price is likely driven primarily by commercialization milestones, reimbursement developments, regulatory progress, and investor confidence in its transplant diagnostics strategy.

•

The company has very limited reported revenue of about $239,000 for the referenced quarter and a net loss of about $11.26 million, so valuation is not currently supported by profitability.

•

Its EV-to-revenue ratio is very high at about 68.5, which means the market is valuing future growth potential rather than current sales.

•

The stock’s beta of 1.823 indicates elevated volatility, and as a micro-cap diagnostics company its shares may react sharply to news, volume changes, financing announcements, clinical data, or payer decisions.

•

Broader healthcare technology sentiment, AI and diagnostics enthusiasm, interest rates, risk appetite, and biotech funding conditions can also influence the stock price.

Recent News

•

Recent company news centered on the rebrand from OncoCyte Corporation to Insight Molecular Diagnostics Inc. and the change in Nasdaq ticker from OCX to IMDX beginning June 18, 2025.

•

The company also announced that its principal executive office is moving to Nashville, Tennessee, where its CLIA-certified laboratory is located.

•

The rebrand reflects a broader strategic focus beyond oncology, especially the growing transplant diagnostics portfolio.

•

The company retired the VitaGraft name and consolidated its transplant products under the GraftAssure brand, including GraftAssureCore, GraftAssureIQ, and GraftAssureDx.

•

IMDX also planned to exhibit at the European Society for Organ Transplantation Congress in London and promote its GraftAssureIQ pilot site program with transplant centers.

Market Trends

•

IMDX operates within a healthcare market that is increasingly focused on precision medicine, molecular diagnostics, data-driven clinical decisions, and noninvasive disease monitoring.

•

Transplant medicine is moving toward biomarkers such as donor-derived cell-free DNA to detect rejection risk earlier and reduce reliance on more invasive methods.

•

Oncology diagnostics continues to grow as physicians use molecular tests to guide treatment selection, recurrence risk assessment, and clinical trial enrollment.

•

Broader healthcare technology trends, including AI, automation, cloud infrastructure, and real-time clinical analytics, may support demand for advanced diagnostics and integrated testing platforms.

•

At the same time, reimbursement scrutiny, hospital budget pressure, regulatory uncertainty, geopolitical cost pressures, and competition from larger diagnostics companies may limit adoption and increase execution risk.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on IMDX

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show